Healthcare Resource Utilization (HCRU) and Costs for Patients (pts) with Metastatic Renal Cell Carcinoma (mrcc) Receiving First-Line (LOT1) Pembrolizumab Plus Axitinib (P+A) or Ipilimumab Plus Nivolumab (I+N).
Journal of clinical oncology（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要